FASL -844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer

Journal of Experimental Medicine

Volumn 202, Issue 7, 2005, Pages 967-974

  Sun, Tong ^a   Zhou, Yifeng ^a   Li, Hua ^a   Han, Xiaohong ^b   Shi, Yuankai ^b   Wang, Li ^a   Miao, Xiaoping ^a   Tan, Wen ^a   Zhao, Dan ^a   Zhang, Xuemei ^a   Guo, Yongli ^a   Lin, Dongxin ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^b CANCER HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ALLELE; ARTICLE; CANCER RISK; CELL ACTIVATION; CELL DEATH; CELL STIMULATION; CHINESE; CONTROLLED STUDY; EX VIVO STUDY; FEMALE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HELA CELL; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; T LYMPHOCYTE; UTERINE CERVIX CANCER;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CASE-CONTROL STUDIES; CELL DEATH; CHINA; CYCLOPHOSPHAMIDE; FAS LIGAND PROTEIN; FEMALE; FLOW CYTOMETRY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HELA CELLS; HUMANS; INTERLEUKIN-2; LEUKOCYTES, MONONUCLEAR; LINKAGE DISEQUILIBRIUM; MELPHALAN; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; POLYMORPHISM, GENETIC; RISK FACTORS; SEMUSTINE; T-LYMPHOCYTES; TUMOR NECROSIS FACTORS; UTERINE CERVICAL NEOPLASMS;

EID: 25844485937     PISSN: 00221007     EISSN: 00221007     Source Type: Journal    
DOI: 10.1084/jem.20050707     Document Type: Article

References (40)

1. Green, D.R., N. Droin, and M. Pinkoski. 2003. Activation-induced cell death in T cells. Immunol. Rev. 193:70-81.
2. Green, D.R., R.P. Bissonnette, J.M. Glynn, and Y. Shi. 1992. Activation-induced apoptosis in lymphoid systems. Semin. Immunol. 4:379-388.
3. Kabelitz, D., T. Pohl, and K. Pechhold. 1993. Activation-induced cell death (apoptosis) of mature peripheral T lymphocytes. Immunol. Today. 14:338-339.
4. Maher, S., D. Toomey, C. Condron, and D. Bouchier-Hayes. 2002. Activation-induced cell death: the controversial role of FAS and FAS ligand in immune privilege and tumour counterattack. Immunol. Cell Biol. 80:131-137.
5. Chappell, D.B., and N.P. Restifo. 1998. T cell-tumor cell. A fatal interaction? Cancer Immunol. Immunother. 47:65-71.
6. Ju, S.T., D.J. Panka, H. Cui, R. Ettinger, M. el-Khatib, D.H. Sherr, B.Z. Stanger, and A. Marshak-Rothstein. 1995. FAS (CD95)/FASL interactions required for programmed cell death after T-cell activation. Nature. 373:444-448.
7. Zaks, T.Z., D.B. Chappell, S.A. Rosenberg, and N.P. Restifo. 1999. FAS-mediated suicide of tumor-reactive T cells following activation by specific tumor. Selective rescue by caspase inhibition. J. Immunol. 162: 3273-3279.
8. + tumor-infiltrating lymphocytes are primed for FAS-mediated activation-induced cell death but are not apoptotic in situ. J. Immunol. 166:6074-6083.
9. Griffith, T.S., T. Brunner, S.M. Fletcher, D.R. Green, and T.A. Ferguson. 1995. FAS ligand-induced apoptosis as a mechanism of immune privilege. Science. 270:1189-1192.
10. Rabinowich, H., T.E. Reichert, Y. Kashii, B.R. Gastman, M.C. Bell, and T.L. Whiteside. 1998. Lymphocyte apoptosis induced by FAS ligand-expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes. J. Clin. Invest. 101:2579-2588.
11. O'Connell, J., G.C. O'Sullivan, J.K. Collins, and F. Shanahan. 1996. The FAS counterattack: FAS-mediated T cell killing by colon cancer cells expressing FAS ligand. J. Exp. Med. 184:1075-1082.
12. Walboomers, J.M., M.V. Jacobs, M.M. Manos, F.X. Bosch, J.A. Kummer, K.V. Shah, P.J. Snijders, J. Peto, C.J. Meijer, and N. Munoz. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189:12-19.
13. Magnusson, P.K., P. Sparen, and U.B. Gyllensten. 1999. Genetic link to cervical tumours. Nature. 400:29-30.
14. Apple, R.J., H.A. Erlich, W. Klitz, M.M. Manos, T.M. Becker, and C.M. Wheeler. 1994. HLA DR-DQ Associations with cervical carcinoma show papillomavirus-type specificity. Nat. Genet. 6:157-162.
15. Contreras, D.N., P.H. Krammer, R.K. Potkul, P. Bu, J.L. Rossi, A.M. Kaufmann, L. Gissmann, and L. Qiao. 2000. Cervical cancer cells induce apoptosis of cytotoxic T lymphocytes. J. Immunother. 23:67-74.
16. Kase, H., Y. Aoki, and K. Tanaka. 2003. Fas ligand expression in cervical adenocarcinoma relevance to lymph node metastasis and tumor progression. Gynecol. Oncol. 90:70-74.
17. Reesink-Peters, N., B.W. Hougardy, F.A. van der Heuvel, K.A. Ten Hoor, H. Hollema, H.M. Boezen, E.G. de Vries, S. de Jong, and A.G. van de Zee. 2005. Death receptors and ligands in cervical carcinogenesis: an immunohistochemical study. Gynecol. Oncol. 96:705-713.
18. Wu, J., C. Metz, X. Xu, R. Abe, A.W. Gibson, J.C. Edberg, J. Cooke, F. Xie, G.S. Cooper, and R.P. Kimberly. 2003. A novel polymorphic CAAT/enhancer-binding protein β element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients. J. Immunol. 170:132-138.
19. Huang, Q.R., D. Morris, and N. Manolios. 1997. Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol. Immunol. 34:577-582.
20. Sibley, K., S. Rollinson, J.M. Allan, A.G. Smith, G.R. Law, P.L. Roddam, C.F. Skibola, M.T. Smith, and G.J. Morgan. 2003. Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res. 63:4327-4330.
21. Sun, T., X. Miao, X. Zhang, W. Tan, P. Xiong, and D. Lin. 2004. Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J. Natl. Cancer Inst. 96:1030-1036.
22. Zhang, X., X. Miao, T. Sun, W. Tan, S. Qu, P. Xiong, Y. Zhou, and D. Lin. 2005. Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer. J. Med. Genet. 42:479-484.
23. Lai, H.C., H.K. Sytwu, C.A. Sun, M.H. Yu, C.P. Yu, H.S. Liu, C.C. Chang, and T.Y. Chu. 2003. Single nucleotide polymorphism at FAS promoter is associated with cervical carcinogenesis. Int. J. Cancer. 103:221-225.
24. Dybikowska, A., W. Sliwinski, J. Emerich, and A.J. Podhajska. 2004. Evaluation of FAS gene promoter polymorphism in cervical cancer patients. Int. J. Mol. Med. 14:475-478.
25. Engelmark, M.T., K.Y. Renkema, and U.B. Gyllensten. 2004. No evidence of the involvement of the FAS -670 promoter polymorphism in cervical cancer in situ. Int. J. Cancer. 112:1084-1085.
26. Davidson, W.F., T. Giese, and T.N. Fredrickson. 1998. Spontaneous development of plasmacytoid tumors in mice with defective Fas-Fas ligand interactions. J. Exp. Med. 187:1825-1828.
27. Peters, A.M., B. Kohfink, H. Martin, F. Griesinger, B. Wormann, M. Gahr, and J. Roesler. 1999. Defective apoptosis due to a point mutation in the death domain of CD95 associated with autoimmune lymphoproliferative syndrome, T-cell lymphoma, and Hodgkin's disease. Exp. Hematol. 27:868-874.
28. Lee, S.H., M.S. Shin, W.S. Park, S.Y. Kim, S.M. Dong, J.H. Pi, H.K. Lee, H.S. Kim, J.J. Jang, C.S. Kim, et al. 1999. Alterations of Fas (Apo-1/CD95) gene in transitional cell carcinomas of urinary bladder. Cancer Res. 59:3068-3072.
29. Lee, S.H., M.S. Shin, W.S. Park, S.Y. Kim, S.H. Kim, J.Y. Han, G.S. Park, S.M. Dong, J.H. Pi, C.S. Kim, et al. 1999. Alterations of Fas (Apo-1/CD95) gene in non-small cell lung cancer. Oncogene. 18:3754-3760.
30. Takahashi, T., M. Tanaka, C.I. Brannan, N.A. Jenkins, N.G. Copeland, T. Suda, and S. Nagata. 1994. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell. 76:969-976.
31. Bennett, M.W., J. O'Connell, G.C. O'Sullivan, C. Brady, D. Roche, J.K. Collins, and F. Shanahan. 1998. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltration lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J. Immunol. 160:5669-5675.
32. Picken, R.N., and H.L. Yang. 1987. The integration of HPV-18 into HeLa cells has involved duplication of part of the viral genome as well as human DNA flanking sequences. Nucleic Acids Res. 15:10068.
33. Kather, A., A. Ferrara, M. Nonn, M. Schinz, J. Nieland, A. Schneider, M. Durst, and A.M. Kaufmann. 2003. Identification of a naturally processed HLA-A*0201 HPV18 E7 T cell epitope by tumor cell mediated in vitro vaccination. Int. J. Cancer. 104:345-353.
34. Sun, T., X. Miao, X. Zhang, and D. Lin. 2004. RESPONSE: Re: Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J. Natl. Cancer Inst. 96:1479.
35. Kanemitsu, S., K. Ihara, A. Saifddin, T. Otsuka, T. Takeuchi, J. Nagayama, M. Kuwano, and T. Hara. 2002. A functional polymorphism in FAS (CD95/APO-1) gene promoter associated with systemic lupus erythematosus. J. Rheumatol. 29:1183-1188.
36. Sun, T., X. Miao, J. Wang, W. Tan, Y. Zhou, C. Yu, and D. Lin. 2004. Functional Phe31Ile polymorphism in Aurora A and risk of breast carcinoma. Carcinogenesis. 25:2225-2230.
37. Nguyen, T., and J. Russell. 2001. The regulation of FASL expression during activation-induced cell death (AICD). Immunology. 103:426-434.
38. Kleinbaum, D.G., L.L. Kupper, and H. Morgenstern. 1982. Epidemiologic Research: Principles and Quantitative Methods. Lifetime Learning Publications, London. 529 pp.
39. Stephens, M., N.J. Smith, and P. Donnelly. 2001. A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet. 68:978-989.
40. Zapata, C., G. Alvarez, and C. Carollo. 1997. Approximate variance of the standardized measure of genetic disequilibrium D′. Am. J. Hum. Genet. 61:771-774.